Centre for Addiction and Mental Health psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Centre for Addiction and Mental Health is listed with 10 registered studies counted here, in Toronto, Canada. By compound: 8 psilocybin and 2 ketamine. By registry status: 3 recruiting, 1 not yet recruiting, 1 active, not recruiting and 5 completed. By phase: 2 phase 1, 6 phase 2 and 2 not applicable. Reported start years run from 2021 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 10 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 8 |
| Ketamine | 2 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 3 | 30% |
| Not yet recruiting | 1 | 10% |
| Active, not recruiting | 1 | 10% |
| Completed | 5 | 50% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 2 | 20% |
| Phase 2 | 6 | 60% |
| Not applicable | 2 | 20% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression | NCT07211438 | Recruiting | Phase 2 | 2026-04-01 | Psilocybin |
| Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder | NCT07405606 | Not yet recruiting | Phase 2 | 2026-03-01 | Psilocybin |
| Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST) | NCT06512220 | Recruiting | Phase 2 | 2025-04-21 | Psilocybin |
| Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) | NCT06518720 | Recruiting | Phase 2 | 2025-04-01 | Psilocybin |
| Psilocybin for Treatment-Resistant Depression in Autism | NCT06731621 | Active, not recruiting | Phase 1 | 2024-11-01 | Psilocybin |
| Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD | NCT06299319 | Completed | Phase 1 | 2024-09-01 | Psilocybin |
| Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment | NCT06041152 | Completed | Phase 2 | 2023-11-27 | Psilocybin |
| Does Psilocybin Require Psychedelic Effects to Treat Depression? | NCT05710237 | Completed | Phase 2 | 2023-07-01 | Psilocybin |
| Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression | NCT05177146 | Completed | Not applicable | 2022-05-04 | Ketamine |
| Intranasal Ketamine in Ultra-REsistant Depression (SURE-ECT Non Responders) | NCT05137938 | Completed | Not applicable | 2021-10-25 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.